Related papers: Optimizing Prediction of MGMT Promoter Methylation…
Glioblastoma is a common brain malignancy that tends to occur in older adults and is almost always lethal. The effectiveness of chemotherapy, being the standard treatment for most cancer types, can be improved if a particular genetic…
The number of studies on deep learning for medical diagnosis is expanding, and these systems are often claimed to outperform clinicians. However, only a few systems have shown medical efficacy. From this perspective, we examine a wide range…
Glioblastomas are the most common malignant brain tumors in adults. Approximately 200000 people die each year from Glioblastoma in the world. Glioblastoma patients have a median survival of 12 months with optimal therapy and about 4 months…
Glioblastoma (GBM) is a highly aggressive primary brain tumor with limited therapeutic options and poor prognosis. The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a critical molecular biomarker…
Glioblastoma Multiforme (GBM) is an aggressive form of malignant brain tumor with a generally poor prognosis. Treatment usually includes a mix of surgical resection, radiation therapy, and akylating chemotherapy but, even with these…
The presence of MGMT promoter methylation significantly affects how well chemotherapy works for patients with Glioblastoma Multiforme (GBM). Currently, confirmation of MGMT promoter methylation relies on invasive brain tumor tissue…
Brain tumors pose significant health challenges worldwide, with glioblastoma being one of the most aggressive forms. Accurate determination of the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is crucial for…
Glioblastoma, an aggressive brain cancer, is amongst the most lethal of all cancers. Expression of the O6-methylguanine-DNA-methyltransferase (MGMT) gene in glioblastoma tumor tissue is of clinical importance as it has a significant effect…
Background and aim: This study aimed to predict methylation status of the O-6 methyl guanine-DNA methyl transferase (MGMT) gene promoter status by using MRI radiomics features, as well as univariate and multivariate analysis. Material and…
Glioblastomas, constituting over 50% of malignant brain tumors, are highly aggressive brain tumors that pose substantial treatment challenges due to their rapid progression and resistance to standard therapies. The methylation status of the…
GBM is a highly aggressive primary malignancy in adults, necessitating personalized therapeutic strategies due to its inherent molecular heterogeneity. MGMT promoter methylation is a pivotal prognostic biomarker for anticipating response to…
GBM (Glioblastoma multiforme) is the most aggressive type of brain tumor in adults that has a short survival rate even after aggressive treatment with surgery and radiation therapy. The changes on magnetic resonance imaging (MRI) for…
Radiomic models have been shown to outperform clinical data for outcome prediction in glioblastoma (GBM). However, clinical implementation is limited by lack of parameters standardization. We aimed to compare nine machine learning…
Gliomas are the most common primary brain malignancies, with different degrees of aggressiveness, variable prognosis and various heterogeneous histologic sub-regions, i.e., peritumoral edematous/invaded tissue, necrotic core, active and…
Glioblastoma is one of the most aggressive and deadliest types of brain cancer, with low survival rates compared to other types of cancer. Analysis of Magnetic Resonance Imaging (MRI) scans is one of the most effective methods for the…
Currently, there is a noticeable lack of AI in the medical field to support doctors in treating heterogenous brain tumors such as Glioblastoma Multiforme (GBM), the deadliest human cancer in the world with a five-year survival rate of just…
In this paper we propose a method for predicting the status of MGMT promoter methylation in high-grade gliomas. From the available MR images, we segment the tumor using deep convolutional neural networks and extract both radiomic features…
Glioblastomas are the most aggressive fast-growing primary brain cancer which originate in the glial cells of the brain. Accurate identification of the malignant brain tumor and its sub-regions is still one of the most challenging problems…
The aim of the systematic review was to assess recently published studies on diagnostic test accuracy of glioblastoma treatment response monitoring biomarkers in adults, developed through machine learning (ML). Articles were searched for…
Precise prognostic modeling of glioblastoma (GBM) under varying treatment interventions is essential for optimizing clinical outcomes. While generative AI has shown promise in simulating GBM evolution, existing methods typically treat…